Microbiomes Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, France, UK, Japan - Size and Forecast 2024-2028

Microbiomes Market Forecast 2024-2028

The global microbiomes market size is estimated to grow by USD 1.13 billion at a CAGR of 22.67% between 2023 and 2028. 

Market players are significantly focusing on collaborations as their primary strategy to gain access to better technologies and to efficiently develop their products that are under various stages of clinical trials or research. Market players are also using collaborative strategies to increase the scope of cross-selling their products and expand their reach in untapped markets. For instance, in February 2021, Ferring Pharmaceutical, Rebiotix, and MyBiotics collaborated to develop live microbiome-based therapeutics in reproductive medicine and maternal health. Moreover, a significant number of such collaborations also assure the rapid entry of new, reliable, and effective microbiome-based therapeutic and diagnostic products shortly for the cost-effective treatment of various complications. Thus, such factors are expected to drive the growth of the market during the forecast period. It also includes an in-depth analysis of drivers, trends, and challenges. Besides analyzing the current market scenario, our report examines historical data from 2018-2022.

What will be the Size of the Market During the Forecast Period?

To learn more about this report, Download Report Sample

Market Segmentation

In the market, organizations like BARDA and BiomeBank explore therapies targeting prevalent diseases using bacteriophages, bacteria, fungi, viruses, and protozoa. Developing medicinal drugs and enzymes as therapeutic agents is crucial, albeit challenging due to the cost of products. Understanding the prevalence of target diseases aids in refining treatment approaches. Collaboration between stakeholders drives innovation, aiming to leverage the potential of microbiomes in addressing diverse health concerns.

Technavio has segmented the market into Product, Application, and Geography. The product segment includes probiotics, foods, prebiotics, medical food, and others. The application segment includes therapeutics and diagnostics, and the geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW)

By Product

The market share growth by the probiotics segment will be significant during the forecast period. Several microbes are used as probiotics, many of which belong to the Bifidobacterium, Bacillus, or Saccharomyces species or members of the Lactobacillaceae family. The range of probiotic species is growing rapidly as scientists learn more about the microbes that reside in the healthy human body. Probiotic products must contain adequate amounts of live microorganisms that are beneficial to confer health benefits.

Get a glance at the market contribution of various segments Download PDF Sample

The probiotics segment was valued at USD 71.21 million in 2018.  Some other benefits of various strains of Bifidobacterium might include reducing symptoms of inflammatory bowel disease, lowering the risk of necrotizing enterocolitis in infants, reducing post-antibiotic diarrhea, preventing the growth of harmful bacteria, and improving colon regularity. Thus, such factors are expected to drive the growth of the probiotics segment in the global microbiomes market during the forecast period. 

By Application

The therapeutics segment dominates the market. Genomic analysis of microbial communities using high-throughput techniques has helped researchers understand the function and composition of the gut microbiota. Microbiome research opens up new opportunities for therapeutic development. Most of the microbiome-based therapeutic products in development aim to modify the gut microbiota using probiotics and prebiotics. Nevertheless, a new approach known as the postbiotic approach, which focuses on the production of specific molecules and directly affects the host, offers significant potential and improved efficiency in the treatment of a wide variety of diseases. The development of such therapeutic approaches will lead to the commercial availability of a large number of microbiome-based therapeutic products during the forecast period. 

Microbiome-based diagnostic approaches are finding wide applications as biomarkers in detecting pathogenic infections and monitoring chronic diseases. Market players such as ENTEROME, 4D Pharma PLC, Pendulum Therapeutics Inc., and Evelo Biosciences are focusing on developing microbiome-derived biomarkers, drug targets, and bioactive molecules for use in the diagnosis of various complex diseases such as cancer and IBD. Moreover, microbiome-based diagnostic approaches are finding use in monitoring the progression of chronic diseases such as cancer and IBD. Such factors are expected to drive the growth of the diagnostics segment in the market during the forecast period. 

By Region

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 43% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. North America dominates the global microbiome market, with the US being the leading country. Growing focus on microbiome-based clinical trials and the prevalence of gastrointestinal and non-gastrointestinal diseases are fueling market growth in the region. Additionally, the North American microbiome market is driven by a large number of well-known vendors focusing on product research and development through collaboration and joint venture strategies. Hence, such factors are expected to drive market growth in this region during the forecast period.

Buy Full Report Now

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

BiomX Inc.: The company offers microbiomes such as BX005, BX004. 

• AOBiome LLC
• DuPont de Nemours Inc.
• Eligo Bioscience
• ENTEROME SA
• Evelo Biosciences Inc.
• ExeGi Pharma
• Ferring BV
• MaaT Pharma
• OraSure Technologies Inc.
• Osel Inc.
• Pendulum Therapeutics Inc.
• PureTech Health Plc
• Qualigen Therapeutics Inc.
• Second Genome Therapeutics
• Seres Therapeutics Inc.
• Synlogic Inc.
• Takeda Pharmaceutical Co. Ltd.
• Vedanta Biosciences Inc.
• YSOPIA Bioscience

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Dynamics, and Customer Landscape

 

The market encompasses various elements such as bacteriophages, fungi, viruses, and protozoa, influencing health and disease. Medicinal drugs and enzymes play vital roles in microbiome modulation. Companies like Finch Therapeutics and Hudson Institute focus on portfolio enhancement through innovative therapies like CP101 and SER-287, targeting conditions like Clostridioides difficile illness. With clinical trial research progressing through Phase I and Phase II, attention on antimicrobial resistance genes and Fecal microbiota therapy (FMT) underscores efforts to address medical care challenges while adhering to regulatory guidelines and managing costs of products. There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. 

Key Market Drivers

The increasing initiatives and investments in microbiome research is the key factor driving the growth of the market. The completion of large microbiome databases, such as the Human Microbiome Database and MetaHIT, has produced vast metagenomic data sets that are widely used to comprehend the intricacy, variability, and impacts of microbial communities. The availability of these data sets and their potential to create innovative microbiome-based therapeutics and diagnostic products have caught the attention of public and private funding organizations that have invested in various microbiome research projects worldwide.

Moreover, government organizations are also dedicating funding to microbiome research to preserve valuable metagenomic data that can be utilized to create effective drug candidates based on specific microbial communities. These initiatives are fostering the development of efficient and effective microbiome therapies and diagnostic tools, which are assisting governments in controlling healthcare expenditure by reducing the burden of diseases and treatment costs, which will drive the growth of the market during the forecast period.

Significant Market Trends

A growing focus on developing biosensors and genetic circuits is the primary trend shaping market growth. The growth of research to develop highly effective and fully autonomous cell-based therapies using the microbiome necessitated the creation of a library of characterized biosensors and genetic circuits. Biosensors and genetic circuits are biocomputing tools used to genetically modify and program cells to perform desired functions.

In addition, the growing understanding of synthetic biology has generated a vast amount of genetic information that can be used to develop biosensors. Biosensors are gaining popularity among vendors as a new category of therapeutic and diagnostic tools, which are expected to boost research activities to develop low-cost diagnostic and therapeutic products during the forecast period.

Major Market Challenges

Challenges related to manufacturing and formulation will impede market growth. Manufacturers of microbiome therapeutics and diagnostics often face complex situations in clinical development, manufacturing, and technology. Producing stable grafts, finding suitable biosensors, producing robust genomes while maintaining safety and bio content standards, and effectively designing microbial therapeutics are some of the challenges vendors face during manufacturing and formulation operations.

Furthermore, market players often have difficulty growing microorganisms during the research and development of drug candidates. The challenges associated with microbial culture are particularly encountered during the isolation, screening, and amplification of any particular strain or species. Also, further processing of the culture used in the development of microbiome-based therapeutic and diagnostic products is a largely unexplored area, further complicating the process, which may impede the growth of the market during the forecast period.

Buy Now Full Report

Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market forecasting report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Segment Overview

The market forecast report forecasts market growth by revenue at global, regional & country levels and analyzes the latest trends and growth opportunities from 2018 to 2028. 

• Product Outlook
  • Probiotics
  • Foods
  • Prebiotics
  • Medical food
  • Others

• Application Outlook
  • Therapeutics
  • Diagnostics

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World (ROW)
    • Brazil
    • Argentina
    • Australia

Market Analyst Overview:

In the burgeoning field of microbiome research, advancements are being made in understanding its impact on various health conditions such as autistic spectrum disorder, chronic hepatitis B, and infectious illness. With increased antibiotic usage, there's a growing focus on microbiome-based diagnostics facilitated by diagnostic instruments and next-generation sequencing (NGS) technology. Key players are investing heavily in R&D, with initiatives like the Human Microbiome Project and Microbiota Restoration Therapy (MRT). Strategic collaborations and external funding are driving innovation in developing novel drugs for conditions like insulin resistance, obesity, liver disorders, and metabolic disorders.

Additionally, In the realm of microbiome drugs research, significant strides are being made in the development of infectious disease diagnostics, fueled by substantial R&D investment from organizations like the National Institutes of Health. Conditions like difficile infection are being targeted with innovative treatments such as those developed by OpenBiome and Blautix, offering hope for patients with IBS-C and IBS-D. Furthermore, pricing analysis and patent analysis are shaping the landscape of the microbiome-based diagnostics market, particularly in addressing conditions like diabetes where microbiome interventions hold promising therapeutic potential.

Market Scope
Report Coverage	Details
Page number	163
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 22.67%
Market Growth 2024-2028	USD 1,13 billion
Market structure	Fragmented
YoY growth 2023-2024(%)	21.77
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 43%
Key countries	US, Germany, France, UK, and Japan
Competitive landscape	Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
Key companies profiled	AOBiome LLC, BiomX Inc., DuPont de Nemours Inc., Eligo Bioscience, ENTEROME SA, Evelo Biosciences Inc., ExeGi Pharma, Ferring BV, MaaT Pharma, OraSure Technologies Inc., Osel Inc., Pendulum Therapeutics Inc., PureTech Health Plc, Qualigen Therapeutics Inc., Second Genome Therapeutics, Seres Therapeutics Inc., Synlogic Inc., Takeda Pharmaceutical Co. Ltd., Vedanta Biosciences Inc., YSOPIA Bioscience, and THERIVA BIOLOGICS INC.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
• Precise estimation of the market size and its contribution to the parent market
• Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
• Growth of the market across Europe, North America, APAC, South America, and Middle East and Africa
• Thorough market growth analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch